New hope for elderly lymphoma patients: experimental combo targets Tough-to-Treat cancer
NCT ID NCT07397832
Summary
This study is testing a new three-drug combination (Chidamide, Rituximab, and Polatuzumab Vedotin) for elderly patients with a specific, aggressive type of lymphoma who have not yet received treatment. The main goal is to see how well this regimen works to eliminate the cancer and how safe it is for older adults. Researchers will measure if the cancer completely disappears and monitor patients' quality of life and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Insititute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.